stonks4u
Sign up free
CAI logo

CAI Caris Life Sciences, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$21.80
-0.38 (-1.71%)

Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its…

Market Cap: $6.16Bwww.carislifesciences.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 17Aug 17

Quote

Day Range
$21.45 – $22.43
52-Week Range
$14.19 – $42.50
Volume
$3.87M
Market Cap
$6.16B
50-Day Avg
$17.77
200-Day Avg
$21.12
Prev Close
$22.18
Open
$22.26

Valuation & Ratios

P/E Ratio
-14.13
EPS
$-1.91
P/B Ratio
13.19
P/S Ratio
9.38
Debt/Equity
0.66
Current Ratio
7.85
Dividend Yield
+0.0%
Gross Margin
+66.4%

Returns & Efficiency

Return on Equity
-93.2%
Return on Assets
-47.8%
FCF Yield
+0.9%
EV/EBITDA
632.55

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$812.03M$-537.96M$-1.91
2024$412.26M$-281.89M$-2.70
2023$306.13M$-341.42M$-1.82
2022$258.49M$-320.83M$-1.57
2020$294.01M$27.73M$1.55

Social Signal Score

50
5d
51
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

Wed, Nov 4(in 3 months)

Consensus estimate $0.03 per share

4of 7 quarters beat consensus

Typical surprise +145.5% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, Aug 5$-0.00 vs $0.01miss
  • Thu, May 7$-0.00 vs $-0.02beat
  • Thu, Feb 26$0.28 vs $0.01beat
  • Wed, Nov 5$0.08 vs $-0.08beat
  • Tue, Aug 12$-0.54 vs $-0.21miss
  • Mon, Jun 9$-0.35 vs $-0.22miss

Estimates and results for CAI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by CAI officers and directors.

Bought
$2.4m

6 trades

Sold
$1.7m

2 trades

  • Halbert Jonbought
    director·68,000 @ $14.56·$990k·May 15, 2026·filing
  • Vacirca Jeff Lbought
    director·31,050 @ $16.15·$501k·May 11, 2026·filing
  • Power Luke Thomassold
    See Remarks·60,850 @ $26.56·$1.6m·Dec 11, 2025·filing
  • Power Luke Thomassold
    See Remarks·1,400 @ $27.16·$38k·Dec 11, 2025·filing
  • Denton John Russelbought
    See Remarks·4,184 @ $24.09·$101k·Nov 7, 2025·filing
  • Spetzler David Baxleybought
    President·400 @ $23.85·$10k·Nov 7, 2025·filing
  • Denton John Russelbought
    See Remarks·7,500 @ $21.00·$158k·Jun 20, 2025·filing
  • Brille Brian Jbought
    director, officer: See Remarks·30,000 @ $21.00·$630k·Jun 20, 2025·filing

92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

CAIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsdefenseworld.net·6h ago·Neutral

    Head to Head Comparison: Caris Life Sciences (CAI) vs. Its Competitors Caris Life Sciences (NASDAQ: CAI - Get Free Report) is one of 110 public companies in the "Life Sciences Tools and Services" industry, but how does it contrast to its rivals? We will compare Caris Life Sciences to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, earnings, dividends and institutional ownership.

    View source ↗